ClinicalTrials.gg
RecruitingNCT02434445Updated Dec 16, 2024

Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients

An observational study in Hepatorenal Syndrome, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by The University of Hong Kong · Observational

How we know

From the registry’s dates

  • Started Jun 2012; still recruiting 14 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
18 Years to 90 Years
Sex
All
01

Study summary

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers investigated include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

Read the detailed description

This study investigated the use of novel plasma and urinary biomarkers to predicte the development of hepatorenal syndrome in patients with advanced cirrhosis. The biomarkers tested include plasma cystatin C, plasma NGAL, plasma NAG, plasma IL-18, plasma ADMA, plasma BTP, urinary KIM-1 and urinary LFABP. These biomarkers will be checked in advanced cirrhotic patients who have or have not developed hepatorenal syndrome and compared between the two groups. These biomarkers will also be correlated with the occurence of hepatorenal syndrome.

02

Conditions studied

  • Hepatorenal Syndrome

Browse trials for

03

In context

Hepatorenal Syndrome

50 studies on the registry are indexed under Hepatorenal Syndrome; 7 are open to participants now.

This study's planned enrollment of 100 is below the median of 140 across 11 observational studies indexed under Hepatorenal Syndrome.

Browse Hepatorenal Syndrome studies →

Lead sponsor

The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with advanced cirrhosis (Child's B or C) referred for liver transplantation
  • Willing to give

Exclusion criteria

Exclusion Criteria:

  • Patients with co-existing renal diseases
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Hepatorenal syndrome group

    Patients with advanced cirrhosis who develope hepatorenal syndrome

  • Non-hepatorenal syndrome group

    Patients with advanced cirrhosis who do not hepatorenal syndrome

06

What researchers measure

Primary outcomes

  1. Hepatorenal syndrome

    Time frame: 12 weeks

Secondary outcomes

  1. Mortality

    Time frame: 6 months

  2. Chronic renal impairment

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2012 (actual). Primary completion is estimated for Dec 2028, 198 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2015
First posted
May 5, 2015
StartActual
Jun 1, 2012
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02434445
Collaborators
The Hong Kong Society of Nephrology
Responsible party
Dr. Desmond Yat-Hin Yap (Clinical Assistant Professor, The University of Hong Kong) — Principal investigator
First posted
May 5, 2015
Start date
Jun 1, 2012
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Dec 16, 2024

Study contacts

Desmond Yap, MD
Contact
desmondy@hku.hk
85222553879
Desmond Yap, MD
principal investigator · The University of Hong Kong

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion